Navigation Links
Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman

EMERYVILLE, Calif., Oct. 3, 2011 /PRNewswire/ -- Redwood Bioscience, a biopharmaceutical company developing a rational protein-chemical design technology for optimizing drug conjugates, announced the appointment of Peter Van Vlasselaer, PhD as Executive Chairman to Redwood's Board of Directors.  In this role, Dr. Van Vlasselaer will be actively guiding Redwood on drug and platform development as well as corporate strategy.  Dr. Van Vlasselaer has been involved in the start-up of four biotechnology companies and brings more than 20 years of senior management experience to Redwood.

Currently, Dr. Van Vlasselaer is the Executive Chairman of iPierian, where he was the interim CEO earlier this year.  He previously served as the founding CEO of Arresto Biosciences which was acquired by Gilead Sciences in December 2010.  Prior to launching Arresto, Dr. Van Vlasselaer was the CEO of Avidia which also had a successful exit though its sale to Amgen in October 2006.  Before that he was involved in the start-up of InterMune and Dendreon where he served as Senior Vice President of Technical Operations and Vice President of Development, respectively.  He holds a bachelor degree in zoology, a PhD in immunology from the University of Leuven in Belgium and conducted post-doctoral research at Stanford University and at DNAX Research Institute.

During his career, Dr. Van Vlasselaer has contributed to the development of multiple biologic products and small molecules for treating diseases including cancer, inflammation, infectious diseases and fibrosis.  He has authored several peer reviewed scientific articles and book chapters and is the inventor on more than 30 patents.

"We are thrilled to welcome Peter to the Executive Chairman role at Redwood," said Karen Boezi, CEO of Redwood.  "His expertise in drug development, operations, corporate strategy and business development will be extremely valuable to the Company."

"We are very pleased to be able to access Peter's proven abilities in shepherding novel technologies from research into the clinic and driving value for investors," stated David Rabuka, co-founder, President & Chief Scientific Officer.

"Redwood stands out as a biotechnology company poised to significantly advance the field of drug conjugates," said Dr. Van Vlasselaer.  "The Company's site specific protein modification technology overcomes the challenges associated with conjugating biologics to synthetic molecules.  By providing control over cargo placement, number and orientation as well as good conjugation efficiency, Redwood is able to generate well defined conjugate libraries for identification of superior antibody-drug conjugates and peptide therapeutics."  

About Redwood Bioscience, Inc.

Redwood Bioscience, an Emeryville, CA based company, is developing a rational protein-chemical design technology to optimize antibody drug conjugates and peptide therapeutics.  The Company's site specific protein modification platform provides unparalleled control over cargo placement on a protein, cargo orientation and stoichiometry, enabling the creation of conjugate libraries from which homogenous compounds with optimal efficacy, safety, and half-life can be selected.  Redwood is located in Emeryville, CA.  For further information, please visit

SOURCE Redwood Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
2. Roka Bioscience Initiates External Trial for AOAC Certification
3. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
4. OBNs 2011 Annual Awards Dinner Celebrates UK Bioscience Success Stories
5. HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College
6. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
7. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
8. BD Biosciences Announces Winners of Research Grant Program
9. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
10. Numira Biosciences Names New Board Member
11. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: ... been advised by its major shareholders, Clean Technology Fund ... United States based venture capital funds ... of Biorem (on a fully diluted, as converted basis), ... disposition of their entire equity holdings in Biorem to ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer ... what they believe could be a new and helpful biomarker for malignant pleural ... Click here to read it now. , Biomarkers are components in the ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):